GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
efficacy, a growing product pipeline, and increasing R&D investments. Rising obesity and diabetes prevalence and improved drug benefits over alternatives further drive demand and market expansion. GLP-1 Receptor Agonist Market GLP-1 Receptor Agonist Market · GlobeNewswire Inc. Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Diabetes, Obesity), Route of Administration, and Region with Growth Forecasts, 2026-2033" report has been added to ResearchAndMarkets.com's offering. The global GLP-1 receptor agonist market size was estimated at USD 70.08 billion in 2025 and is projected to reach USD 201.79 billion by 2033, growing at a CAGR of 12.78% from 2026 to 2033. The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anti
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- GLP-1 drugs linked to lower addiction risk, study finds [USA TODAY]USA TODAY
- Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? [Yahoo! Finance]Yahoo! Finance
- Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
- Eli Lilly Expands Obesity Access As Oral GLP-1 Data Shape Growth Story [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website